Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial

被引:0
|
作者
D'Agostino, Mattia [1 ,2 ]
Antonioli, Elisabetta [3 ]
Gamberi, Barbara [4 ]
Bruno, Benedetto [1 ,2 ]
Derudas, Daniele [5 ]
Tosi, Patrizia [6 ]
Fazio, Francesca [7 ]
Carlo-Stella, Carmelo [8 ,9 ]
Ronconi, Sonia [10 ]
Corradini, Paolo [11 ]
Ballanti, Stelvio [12 ]
Cellini, Claudia [13 ]
Falcone, Antonietta Pia [14 ]
Bringhen, Sara [15 ]
Offidani, Massimo [16 ]
Rambaldi, Alessandro [17 ]
Rota-Scalabrini, Delia [18 ]
Agazzi, Alberto [19 ]
Casaluci, Gloria Margiotta [20 ]
Pietrantuono, Giuseppe [21 ]
Patriarca, Francesca [22 ,23 ]
Larocca, Alessandra [2 ,15 ]
Boccadoro, Mario [24 ]
机构
[1] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[2] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[3] AOU Careggi, UO Ematol, Florence, Italy
[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy
[5] ARNAS G Brozu, Osped Oncol Riferimento Reg A Businco, SC Ematol & CTMO, Cagliari, Italy
[6] Osped Rimini, UO Ematol, Rimini, Italy
[7] Sapienza Univ Rome, Dept Translat & Precis Med, Hematol, Rome, Italy
[8] Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy
[9] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy
[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy
[11] Fdn IRCCS Ist Nazl Tumori, Milan, MI, Italy
[12] Osped Santa Maria Misericordia, Sez Ematol & Immunol Clin, Localita St Andrea Fratte, Perugia, Italy
[13] Osped Santa Maria Croci, UOC Ematol, AUSL Romagna, Ravenna, Italy
[14] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol, San Giovanni Rotondo, Italy
[15] Azienda Osped Univ Citta Salute & Sci Torino, Dept Oncol, SSD Clin Trial Oncoematol & Mieloma Multiplo, Turin, Italy
[16] Azienda Osped Univ Marche, Clin Ematol, Ancona, Italy
[17] ASST Papa Giovanni XXIII, UO Ematol, Bergamo, Italy
[18] FPO IRCCS, Candiolo Canc Inst, Dept Med Oncol, Turin, Italy
[19] European Inst Oncol, Hematoncol Div, Milan, Italy
[20] AOU Maggiore Carita, Novara, Italy
[21] IRCCS Ctr Riferimento Oncol Basilicata, Hematol & Stem Cell Transplantat Unit, Rionero In Vulture, Italy
[22] Univ Udine, Dipartimento Area Med DAME, ASUFC, Clin Ematol, Udine, Italy
[23] Univ Udine, Unita Terapie Cellulari, ASUFC, Clin Ematol, Udine, Italy
[24] European Myeloma Network, Milan, Italy
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P-109
引用
收藏
页码:S94 / S95
页数:2
相关论文
共 50 条
  • [31] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
    Leleu, Xavier
    Hulin, Cyrille
    Lambert, Jerome
    Bobin, Arthur
    Perrot, Aurore
    Manier, Salomon
    Jaccard, Arnaud
    Montes, Lydia
    Karlin, Lionel
    Godmer, Pascal
    Chalopin, Thomas
    Slama, Borhane
    Chretien, Marie Lorraine
    Laribi, Karim
    Dingremont, Claire
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Macro, Margaret
    Mohty, Mohamad
    Touzeau, Cyrille
    Moreau, Philippe
    Avet-Loiseau, Herve
    Corre, Jill
    Facon, Thierry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
  • [32] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
    O'Donnell, Elizabeth K.
    Suman, Vera Jean
    Geyer, Susan M.
    Nadeem, Omar
    Dinner, Shira
    Yee, Andrew J.
    Laubach, Jacob P.
    Mo, Clifton C.
    Tuchman, Sascha A.
    Donadio, Kristen
    Sinclair, Sarah
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [33] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [34] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
    O'Donnell, Elizabeth K.
    Laubach, Jacob P.
    Yee, Andrew J.
    Huff, Carol A.
    Basile, Frank G.
    Wade, Philip M., Jr.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Couture, Nicole R.
    Doherty, Lauren
    Lyons, Hannah
    English, Caroline
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul C.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [35] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [36] A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
    O'Donnell, Elizabeth K.
    Laubach, Jacob P.
    Yee, Andrew J.
    Chen, Tianqi
    Huff, Carol Ann
    Basile, Frank G.
    Wade, Philip M.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Burke, Jill N.
    Harrington, Cynthia C.
    Lively, Kathleen J.
    Lyons, Hannah F.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Trippa, Lorenzo
    Richardson, Paul G.
    Raje, Noopur S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 222 - 230
  • [37] Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
    Leleu, Xavier
    Hulin, Cyrille
    Lambert, Jerome
    Bobin, Arthur
    Perrot, Aurore
    Karlin, Lionel
    Roussel, Murielle
    Montes, Lydia
    Cherel, Brieuc
    Chalopin, Thomas
    Slama, Borhane
    Chretien, Marie-Lorraine
    Laribi, Kamel
    Dingremont, Claire
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Calmettes, Claire
    Dib, Mamoun
    Tiab, Mourad
    Vincent, Laure
    Delaunay, Jacques
    Santagostino, Alberto
    Macro, Margaret
    Bourgeois, Emmanuelle
    Orsini-Piocelle, Frederique
    Gay, Julie
    Bareau, Benoit
    Bigot, Noemie
    Vergez, Francois
    Lebreton, Pierre
    Tabrizi, Reza
    Waultier-Rascalou, Agathe
    Frenzel, Laurent
    Le Calloch, Ronan
    Chalayer, Emilie
    Braun, Thorsten
    Lachenal, Florence
    Corm, Selim
    Kennel, Celine
    Belkhir, Rakiba
    Blade, Jean-Sebastien
    Joly, Bertrand
    Richez-Olivier, Valentine
    Gardeney, Helene
    Demarquette, Helene
    Robu-Cretu, Daniela
    Garderet, Laurent
    Newinger-Porte, Muriel
    Kasmi, Amine
    NATURE MEDICINE, 2024, 30 (08) : 2235 - 2241
  • [38] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    BLOOD, 2023, 142
  • [39] Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
    Gay, Francesca
    Hayman, Suzanne
    Lacy, Martha Q.
    Buadi, Francis
    Gertz, Morie A.
    Kumar, Shaji
    Dispenzieri, Angela
    Mikhael, Joseph R.
    Bergsagel, Leif
    Dingli, David
    Reeder, Craig B.
    Lust, John A.
    Russel, Stephen
    Roj, Vivek
    Zeldenrust, Steven R.
    Witzig, Thomas E.
    Fonseca, Rafael
    Kyle, Robert
    Greipp, Philip R.
    Stewart, A. Keith
    Rajkumar, S. Vincent
    BLOOD, 2009, 114 (22) : 1494 - 1495
  • [40] Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews
    Visacri, Manlia Berlofa
    Ribeiro, Mayra Carvalho
    Komoda, Denis Satoshi
    Duarte, Bruno Kosa Lino
    Correa, Carlos Roberto Silveira
    Maia, Flavia de Oliveira Motta
    Alves, Daniela Fernanda dos Santos
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 43